SEPPIC

SEPPIC is a French specialty-chemicals company that develops and supplies ingredients, excipients, formulation systems, and related technologies for health and wellbeing markets. Its activities span personal care, pharmaceuticals and nutrition, vaccine adjuvants and injectables, and industrial specialties. Rather than operating primarily as a mass-market chemical producer, SEPPIC focuses on functional and formulation-oriented materials whose value depends on performance, compatibility, processing behavior, and suitability for regulated or technically demanding applications. The company was founded in France in 1943 by chemist André Bondouy under the name Société d’exploitation pour les produits de l’industrie chimique. During the first decades of its existence, SEPPIC expanded its commercial role and, between 1946 and 1972, became a distributor for several chemical manufacturers. A significant change came in 1972, when the company acquired Société des Produits Chimiques de la Montagne Noire in Castres. That transaction led to the creation of the MONTANE and Montanox lines of emulsifiers, products intended for cosmetics, pharmaceutical formulations, and industrial uses. SEPPIC became part of the Air Liquide group in 1986 as a wholly owned subsidiary within Air Liquide’s healthcare activities. This ownership connected the company to a large international industrial and healthcare group while allowing SEPPIC to maintain a specialized product and research profile. In 1989, it established its first American subsidiary in Fairfield, New Jersey, supporting expansion in North America. The company later broadened its portfolio through acquisitions, including BiotechMarine in 2013, a specialist in marine-derived cosmetic ingredients and plant stem-cell technologies, and Serdex in 2017, a developer of botanical active ingredients for skin treatment. Research and product development are central to SEPPIC’s identity. The company has reported a portfolio of more than 140 patent families and has worked across emulsifiers, polymers, active ingredients, delivery systems, excipients, and vaccine technologies. Examples associated with its innovation history include Montanov 65, a vegetable-origin emulsifier introduced as an example of early green-chemistry development in the 1990s, and SEPIGEL 305, a pre-neutralized polymer supplied in an inverse-emulsion form that enabled new cosmetic textures such as gel-creams. In healthcare, SEPPIC’s adjuvant technologies were used in work connected with CimaVax, a therapeutic lung-cancer vaccine developed in Cuba and described in reference material as the first therapeutic vaccine of its kind. Today, SEPPIC serves customers through international operations, distributors, and production locations. Its business combines specialty raw materials with application expertise, regulatory knowledge, formulation support, and research partnerships. The company participates in collaborations involving health, nutrition, personal care, and vaccines, including work with international businesses such as Shin-Etsu, and is involved with the French Cosmetic Valley cluster. Its positioning is therefore built around specialized, science-led ingredients and formulation solutions for customers that need differentiated performance rather than commodity chemical volume alone.

SEPPIC was founded in France in 1943 by chemist André Bondouy. Its original French name was Société d’exploitation pour les produits de l’industrie chimique. During the postwar period, the company developed a broad commercial role and from 1946 to 1972 distributed products made by several other chemical manufacturers. In 1972, under the leadership of Jean Martineau, SEPPIC acquired Société des Produits Chimiques de la Montagne Noire in Castres, France. The acquisition expanded the company’s manufacturing and formulation capabilities and led to the development of the MONTANE and Montanox emulsifier lines. These products served cosmetic, pharmaceutical, and industrial customers. A major ownership transition occurred in 1986, when SEPPIC became a wholly owned subsidiary of Air Liquide and was integrated into the group’s healthcare activities. SEPPIC subsequently pursued international development, establishing its first American subsidiary in Fairfield, New Jersey, in 1989. The company also maintained an international network of distributors and production locations. Research became increasingly important to SEPPIC’s growth. In the 1990s, the company developed Montanov 65, an emulsifier derived from vegetable-origin materials. It later introduced SEPIGEL 305, a pre-neutralized polymer supplied in an inverse emulsion that helped formulators create new cosmetic textures, including gel-creams. SEPPIC’s research portfolio has been described as containing more than 140 patent families. The company expanded into newer sources and technologies through acquisitions. In 2013, following the divestiture of a substantial part of its industrial-additives business in 2011, SEPPIC acquired BiotechMarine. That company specialized in marine-based cosmetic ingredients and plant stem-cell technologies. In 2017, SEPPIC completed the acquisition of Serdex, a specialist in botanical active ingredients used in skin-treatment products. SEPPIC has also developed or supplied technologies for healthcare applications. Its adjuvants were used in work connected with CimaVax, a Cuban therapeutic vaccine for lung cancer. Alongside its own research, the company has pursued partnerships in health, nutrition, personal care, and vaccines, including collaborations with international companies such as Shin-Etsu. It is also involved in the Cosmetic Valley business cluster. The modern SEPPIC business is organized around four broad areas: personal care; pharmaceuticals and nutrition; vaccine adjuvants and injectables; and industrial specialties. Across these areas, the company supplies specialty ingredients and formulation technologies rather than undifferentiated bulk chemicals. Its activities combine materials science, biological and botanical research, application development, and support for customers operating in technically regulated markets.

• 2017

  Serdex acquisition

  [1]SEPPICen.wikipedia.org

  SEPPIC finalized the acquisition of Serdex, strengthening its portfolio of botanical skin-treatment actives.

• 2013

  BiotechMarine acquisition

  [1]SEPPICen.wikipedia.org

  SEPPIC acquired BiotechMarine, adding marine-derived cosmetic ingredients and plant stem-cell technologies.

• 2011

  Divestiture of part of the industrial-additives business

  [1]SEPPICen.wikipedia.org

  SEPPIC divested a significant portion of its industrial-additives business before expanding further into specialized cosmetic ingredients.

• 2008

  SEPPIC adjuvants support CimaVax development

  [1]SEPPICen.wikipedia.org

  SEPPIC adjuvant technologies were used in the development of CimaVax, a therapeutic vaccine for lung cancer.

• 1990

  Development of Montanov 65

  [1]SEPPICen.wikipedia.org

  SEPPIC developed Montanov 65, a vegetable-origin emulsifier associated with its early green-chemistry work.

• 1989

  First American subsidiary

  [1]SEPPICen.wikipedia.org

  SEPPIC established its first American subsidiary in Fairfield, New Jersey.

• 1986

  Joins the Air Liquide group

  [1]SEPPICen.wikipedia.org

  SEPPIC became a wholly owned Air Liquide subsidiary within the group’s healthcare activities.

• 1972

  Acquisition of Société des Produits Chimiques de la Montagne Noire

  [1]SEPPICen.wikipedia.org

  The acquisition in Castres helped create the MONTANE and Montanox emulsifier product lines for cosmetic, pharmaceutical, and industrial markets.

• 1943

  SEPPIC is founded in France

  [1]SEPPICen.wikipedia.org

  Chemist André Bondouy founded Société d’exploitation pour les produits de l’industrie chimique, later known as SEPPIC.

Science-led specialty chemicals and formulation technologies for personal care, healthcare, nutrition, vaccines, injectables, and industrial applications.

• Emulsifiers · 1972

  MONTANE

  MONTANE is an emulsifier product family developed after SEPPIC’s acquisition of Société des Produits Chimiques de la Montagne Noire in 1972. The range was designed for use across cosmetic, pharmaceutical, and industrial formulations, where emulsification performance and formulation stability are important.

• Emulsifiers · 1972

  Montanox

  Montanox is an emulsifier line associated with SEPPIC’s Castres operations and the company’s expansion into formulation ingredients for cosmetics, pharmaceuticals, and industrial applications. Specific current products and commercial status are not detailed in the supplied reference material.

• Vegetable-origin emulsifier

  Montanov 65

  Montanov 65 is an emulsifier developed from vegetable-origin materials. SEPPIC presents it as an early example of its green-chemistry approach and as part of the company’s effort to provide formulation ingredients with plant-derived feedstocks for personal-care applications.

• Polymer and texture modifier

  SEPIGEL 305

  SEPIGEL 305 is a pre-neutralized polymer supplied in an inverse-emulsion form. It enabled formulators to create distinctive textures, including gel-creams, and illustrates SEPPIC’s focus on ingredients that deliver both technical performance and sensory effects in personal-care formulations.

• Marine-derived cosmetic ingredients · 2013

  BiotechMarine portfolio

  The BiotechMarine portfolio brought marine-based cosmetic ingredients and plant stem-cell technologies into SEPPIC through the 2013 acquisition. These materials expanded the company’s capabilities in cosmetic actives and nature-derived personal-care ingredients.

• Botanical skin-treatment actives · 2017

  Serdex portfolio

  The Serdex portfolio consists of botanical active ingredients for skin-treatment applications. Its integration into SEPPIC in 2017 strengthened the company’s offering of plant-based and biologically active ingredients for personal-care and dermocosmetic formulations.

• Healthcare formulation technology

  Vaccine adjuvants

  SEPPIC develops adjuvant technologies used to support vaccine formulations and immune-response strategies. Reference material links SEPPIC adjuvants to the development of CimaVax, a therapeutic lung-cancer vaccine, while the supplied sources do not identify a single consumer-facing branded adjuvant range.

• 2017

  Serdex acquisitionM&A

  Background

  SEPPIC continued to expand its portfolio of differentiated cosmetic active ingredients.

  Action taken

  SEPPIC finalized the acquisition of Serdex, a specialist in botanical skin-treatment ingredients.

  Aftermath

  The transaction strengthened SEPPIC’s botanical and dermocosmetic active-ingredient capabilities.

  Source

• 2013

  BiotechMarine acquisitionM&A

  Background

  SEPPIC sought to expand its personal-care capabilities beyond conventional formulation chemicals.

  Action taken

  SEPPIC acquired BiotechMarine, adding marine-based cosmetic ingredients and plant stem-cell technologies.

  Aftermath

  The acquisition broadened SEPPIC’s nature-derived and biotechnology-related offering for cosmetic customers.

  Source

• 2011

  Reduction of industrial-additives exposureStrategy

  Background

  SEPPIC reassessed part of its industrial-additives activity as it developed a more focused specialty-ingredients portfolio.

  Action taken

  The company divested a significant portion of its industrial-additives business.

  Aftermath

  The divestiture was followed by acquisitions in marine-derived cosmetic ingredients and botanical actives.

  Source

• 1986

  Air Liquide acquisitionM&A

  Background

  SEPPIC had developed from a French chemical distributor and specialty-products company into a supplier serving formulation and healthcare markets.

  Action taken

  Air Liquide acquired SEPPIC and made it a wholly owned subsidiary within its healthcare activities.

  Aftermath

  The transaction placed SEPPIC within an international industrial and healthcare group and preceded further international expansion.

  Source

• 2017

  SEPPIC finalizes acquisition of Serdex[1]SEPPICen.wikipedia.org

  M&A

  SEPPIC completed the acquisition of Serdex, a specialist in botanical active ingredients for skin treatment.

• 2013

  SEPPIC acquires BiotechMarine[1]SEPPICen.wikipedia.org

  M&A

  SEPPIC acquired BiotechMarine, a company focused on marine-derived cosmetic ingredients and plant stem-cell technologies.

• 1989

  SEPPIC establishes its first American subsidiary[1]SEPPICen.wikipedia.org

  Other

  The company opened its first American subsidiary in Fairfield, New Jersey, supporting its international expansion.

• 1986

  SEPPIC becomes part of Air Liquide[1]SEPPICen.wikipedia.org

  M&A

  SEPPIC became a wholly owned subsidiary of Air Liquide as part of the group’s healthcare activities.

1. 1SEPPICen.wikipedia.org